Latest & greatest articles for aspirin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on aspirin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on aspirin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Aspirin

Acetylsalicylic acid (ASA) more commonly known as aspirin is a painkiller that has a wide range of uses. It is frequently used to treat fever, mild pain, tooth aches, headaches and muscle aches. Aspirin is a nonsteroidal anti-inflammatory drug (NSAID) and can be used in the management of conditions such as heart attack, arthritis, blood clots and stroke. Aspirin, has been used for thousands of years, initially extracted from the leaves of willow trees.

Aspirin works in much the same way as other NSAIDs but has additional properties, such as antiplatelet activity which can make it additionally useful. More recently aspirin has been linked with cancer prevention. But the potential benefits of aspirin need to be weighed against the potential side effects, which includes gastrointestinal bleeding and Reye’s syndrome. It should be noted that aspirin should not be used in people who are allergic to drugs such as ibuprofen or a more generalized intolerance to NSAIDs. It should also be used cautiously in asthmatics and/or those with bronchospasm associated with NSAID use.

Research evidence, clinical trials and guidelines on Aspirin

The Trip Database has an extensive collection of articles on aspirin ranging from clinical trials, systematic reviews, clinical guidelines and case reports. These can be found via searching the site.

Top results for aspirin

301. Low dose aspirin lowered stroke risk but not risk of myocardial infarction or cardiovascular death in women

Low dose aspirin lowered stroke risk but not risk of myocardial infarction or cardiovascular death in women Low dose aspirin lowered stroke risk but not risk of myocardial infarction or cardiovascular death in women | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low dose aspirin lowered stroke risk but not risk of myocardial infarction or cardiovascular death in women Article Text Treatment Low dose aspirin lowered stroke risk but not risk of myocardial infarction or cardiovascular death in women Free David R

Evidence-Based Nursing (Requires free registration)2006

302. Aspirin, 1000 mg, reduced moderate to severe pain in acute migraine headache

Aspirin, 1000 mg, reduced moderate to severe pain in acute migraine headache Aspirin, 1000 mg, reduced moderate to severe pain in acute migraine headache | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in via your Society Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin, 1000 mg, reduced moderate to severe pain in acute migraine headache Article Text Treatment Aspirin, 1000 mg, reduced moderate to severe pain in acute migraine headache Free Diana E McMillan , RN, PhD Statistics from Altmetric.com No Altmetric data available for this article. Lipton RB, Goldstein

Evidence-Based Nursing (Requires free registration)2006

303. Low dose aspirin lowered stroke risk but not risks of MI or cardiovascular deaths in women

Low dose aspirin lowered stroke risk but not risks of MI or cardiovascular deaths in women Low dose aspirin lowered stroke risk but not risks of MI or cardiovascular deaths in women | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search (...) for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low dose aspirin lowered stroke risk but not risks of MI or cardiovascular deaths in women Article Text Therapeutics Low dose aspirin lowered stroke risk but not risks of MI or cardiovascular deaths in women Free John W Eikelboom , MD Statistics from Altmetric.com No Altmetric data available for this article. Ridker PM

Evidence-Based Medicine (Requires free registration)2006

304. Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis

Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis Article Text Therapeutics Warfarin was not more effective than aspirin and increased adverse events in symptomatic intracranial arterial stenosis Free John

Evidence-Based Medicine (Requires free registration)2006

305. Review: dipyridamole given with or without aspirin reduces recurrent stroke

Review: dipyridamole given with or without aspirin reduces recurrent stroke Review: dipyridamole given with or without aspirin reduces recurrent stroke | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using (...) your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: dipyridamole given with or without aspirin reduces recurrent stroke Article Text Therapeutics Review: dipyridamole given with or without aspirin reduces recurrent stroke Free Graeme J Hankey , MD, FRACP, FRCP Statistics from Altmetric.com No Altmetric data available for this article. Leonardi-Bee J, Bath PM, Bousser MG, et al . Dipyridamole

Evidence-Based Medicine (Requires free registration)2006

306. Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients

Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Article Text Therapeutics Aspirin plus esomeprazole reduced recurrent ulcer bleeding more than clopidogrel in high risk patients Free Walter L Peterson , MD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2006

307. Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy

Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy Article Text Therapeutics Clopidogrel was effective in patients who have MI with ST segment elevation receiving aspirin and fibrinolytic therapy Free Steven

Evidence-Based Medicine (Requires free registration)2006

308. Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease

Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name (...) or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Article Text Therapeutics Picotamide reduced all cause mortality more than aspirin in type 2 diabetes mellitus and peripheral arterial disease Free Donald

Evidence-Based Medicine (Requires free registration)2006

309. Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk

Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk Article Text Therapeutics Review: antiplatelet agents (particularly aspirin) reduce the incidence of pre-eclampsia in women at risk Free Andrew H Shennan , MD Statistics from Altmetric.com

Evidence-Based Medicine (Requires free registration)2006

310. Sex differences in platelet reactivity and response to low-dose aspirin therapy.

Sex differences in platelet reactivity and response to low-dose aspirin therapy. 16551714 2006 03 22 2006 03 24 2016 10 17 1538-3598 295 12 2006 Mar 22 JAMA JAMA Sex differences in platelet reactivity and response to low-dose aspirin therapy. 1420-7 Recent randomized trials suggest that women may not accrue the same cardioprotective benefits as men do from low-dose aspirin therapy used in primary prevention. Failure of aspirin to suppress platelet aggregation in women is one hypothesized (...) mechanism. To examine differential platelet reactivity to low-dose aspirin therapy by sex. A clinical trial of aspirin at 81 mg/d for 14 days was conducted in 571 men and 711 women. Baseline and post-aspirin therapy measures included platelet aggregation to arachidonic acid, adenosine diphosphate, epinephrine, and platelet function analyzer closure time. Sex differences in cyclooxygenase 1 (COX-1) direct and indirect platelet activation pathways before and after administration of aspirin. In 10

JAMA2006

311. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis.

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis. BACKGROUND: Aspirin and statins are both effective for primary prevention of coronary heart disease (CHD), but their combined use has not been well studied. OBJECTIVE: To perform a cost-utility analysis of the effects of aspirin therapy, statin therapy, combination therapy with both drugs, and no pharmacotherapy for the primary prevention of CHD events in men. DESIGN (...) : Markov model. DATA SOURCES: Published literature. TARGET POPULATION: Middle-aged men without a history of cardiovascular disease at 6 levels of 10-year risk for CHD (2.5%, 5%, 7.5%, 10%, 15%, and 25%). TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTIONS: Low-dose aspirin, a statin, both drugs as combination therapy, or no therapy. OUTCOME MEASURE: Cost per quality-adjusted life-year gained. RESULTS OF BASE-CASE ANALYSIS: For 45-year-old men who do not smoke, are not hypertensive

Annals of Internal Medicine2006

312. Aspirin resistance.

Aspirin resistance. Aspirin resistance is the inability of aspirin to reduce platelet production of thromboxane A2 and thereby platelet activation and aggregation. Increasing degrees of aspirin resistance may correlate independently with increasing risk of cardiovascular events. Aspirin resistance can be detected by laboratory tests of platelet thromboxane A2 production or platelet function that depend on platelet thromboxane production. Potential causes of aspirin resistance include inadequate (...) dose, drug interactions, genetic polymorphisms of COX-1 and other genes involved in thromboxane biosynthesis, upregulation of non-platelet sources of thromboxane biosynthesis, and increased platelet turnover. Aspirin resistance can be overcome by treating the cause or causes, and reduced by minimising thromboxane production and activity, and blocking other pathways of platelet activation. Future research is aimed at defining aspirin resistance, developing reliable tests for it, and establishing

Lancet2006

313. Clopidogrel plus aspirin or aspirin alone in unstable angina

Clopidogrel plus aspirin or aspirin alone in unstable angina BestBets: Clopidogrel plus aspirin or aspirin alone in unstable angina Clopidogrel plus aspirin or aspirin alone in unstable angina Report By: Shweta Gidwani - Clinical Effectiveness Fellow Search checked by Richard Body - Clinical Research Fellow Institution: Manchester Royal Infirmary Original author: Shweta Gidwani Original institution: Manchester Royal Infirmary Date Submitted: 25th November 2005 Date Completed: 2nd February 2006 (...) with oxygen, aspirin, nitrates, beta-blockers and heparin, after which he becomes pain free. You also give him clopidogrel 300 mg because you have heard that patients with unstable angina and non ST-elevation MI have a better cardiovascular outcome when treated with a combination of clopidogrel and aspirin versus aspirin alone. You wonder whether there is any evidence to support this. Search Strategy Medline 1966�11/2005 using the OVID interface Embase 1980�2005 week 47 The Cochrane Library Issue 4 2005

BestBETS2006

314. Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis

Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis Aspirin and nonsteroidal anti-inflammatory drug use and risk of pancreatic cancer: a meta-analysis Larsson S C, Giovannucci E, Bergkvist L, Wolk A CRD summary The authors concluded that current evidence does not support a link between aspirin and non-steroidal anti-inflammatory drug use and risk (...) of pancreatic cancer. The limited search, absence of a formal validity assessment and limited details about the included studies make it difficult to assess the reliability of the authors’ conclusions. Authors' objectives To investigate the relationship between use of non-steroidal anti-inflammatory drugs (NSAIDs), including aspirin, and risk of pancreatic cancer. Searching MEDLINE was searched from 1966 to October 2006 for articles in any language; the search terms were reported. The reference lists

DARE.2006

315. Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients

Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Aspirin plus warfarin compared to aspirin alone after acute coronary syndromes: an updated and comprehensive meta-analysis of 25,307 patients Andreotti F, Testa L, Biondi-Zoccai G G, Crea F CRD summary The review (...) investigated the effect of aspirin combined with warfarin in patients recovering from acute coronary syndromes. The review concluded that at an international normalised ratio of 2-3 the combination of aspirin and warfarin is superior to aspirin alone in reducing the risk of major adverse events, although it significantly increases the risk of major bleeding. The conclusion appears reliable. Authors' objectives To determine the effect of aspirin plus warfarin (A+W) compared with aspirin alone

DARE.2006

316. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials

Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials Berger J S, Roncaglioni M C, Avanzini F, Pangrazzi I, Tognoni G, Brown D L CRD (...) summary This review concluded that aspirin reduces the risk of stroke in women and of myocardial infarction in men, but increases the risk of major bleeding for both groups. The conclusion appears to follow from evidence presented, although the search for studies could have been more extensive and the inadequate description of the review methods makes it difficult to verify the findings. Authors' objectives To determine the effect of aspirin in the primary prevention of cardiovascular disease in women

DARE.2006

317. Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation

Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Which patients should receive aspirin for primary prevention of cardiovascular disease: an economic evaluation Annemans L, Lamotte M, Kubin M, Evers T, Verheugt F W Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS (...) EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study evaluated the use of low-dose aspirin (75 to 325 mg) in the primary prevention of cardiovascular disease (CVD). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study population comprised a hypothetical cohort of patients aged

NHS Economic Evaluation Database.2006

318. Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis

Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Aspirin, statins, or both drugs for the primary prevention of coronary heart disease events in men: a cost-utility analysis Pignone M, Earnshaw S, Tice J A, Pletcher M J Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined the use of aspirin, statins, and a combination of aspirin and statins for the primary prevention of coronary heart disease (CHD). Type of intervention Primary prevention. Economic study type Cost-utility analysis. Study population The study

NHS Economic Evaluation Database.2006

319. Aspirin

Aspirin Aspirin ASP Drugs October 2006 Page 1 of 1 Drugs PRESENTATION 300 milligram aspirin (acetylsalicylic acid) in tablet form (dispersible). ACTIONS Has an anti-platelet action which reduces clot formation. Analgesic, anti-pyretic and anti-in?ammatory. CAUTIONS As the likely bene?ts of a single 300 milligram aspirin outweigh the potential risks, aspirin may be given to patients with: Asthma Pregnancy Kidney or liver failure Gastric or duodenal ulcer SIDE EFFECTS Gastric bleeding. Wheezing (...) in some asthmatics. DOSAGE AND ADMINISTRATION Adults Adults with apparent, suspected or possible myocardial infarction. Route: Oral – chewed or dissolved in water INDICATIONS Adults with: clinical or ECG evidence of myocardial infarction or ischaemia central chest pain, possibly of cardiac origin. Aspirin should be administered to any patient with chest pain unless the diagnosis is very clearly non- cardiac or the drug is contraindicated. CONTRA-INDICATIONS Known aspirin allergy or sensitivity

Joint Royal Colleges Ambulance Liaison Committee2006

320. Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis

Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death in high risk atherothrombosis Article Text Therapeutics Clopidogrel plus aspirin did not differ from aspirin alone for reducing MI, stroke, and CV death

Evidence-Based Medicine (Requires free registration)2006